James Anthony Torchia, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Anti-Idiotypic | 1 | 2016 | 356 | 0.480 |
Why?
|
| Vaccines, Synthetic | 1 | 2016 | 617 | 0.440 |
Why?
|
| Protein Engineering | 1 | 2016 | 541 | 0.410 |
Why?
|
| Lymphoma | 3 | 2016 | 1899 | 0.380 |
Why?
|
| Cancer Vaccines | 2 | 2016 | 1046 | 0.360 |
Why?
|
| Hashimoto Disease | 1 | 2023 | 105 | 0.200 |
Why?
|
| Graves Disease | 1 | 2023 | 239 | 0.190 |
Why?
|
| Tumor Escape | 1 | 2023 | 370 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 4 | 2023 | 9185 | 0.110 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2013 | 235 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2013 | 778 | 0.100 |
Why?
|
| Receptors, Immunologic | 2 | 2010 | 1414 | 0.100 |
Why?
|
| Lymphocyte Depletion | 2 | 2013 | 602 | 0.100 |
Why?
|
| Drug Design | 1 | 2016 | 1061 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2010 | 2896 | 0.080 |
Why?
|
| Osteoclasts | 3 | 2010 | 712 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 6130 | 0.080 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2010 | 413 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2013 | 3075 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 3734 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 3709 | 0.070 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2005 | 114 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2007 | 611 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2803 | 0.060 |
Why?
|
| Immunologic Factors | 2 | 2013 | 1588 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2013 | 1249 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 935 | 0.060 |
Why?
|
| Bone Remodeling | 1 | 2007 | 580 | 0.060 |
Why?
|
| Chemokine CX3CL1 | 1 | 2023 | 64 | 0.060 |
Why?
|
| Receptors, Thyrotropin | 1 | 2023 | 45 | 0.050 |
Why?
|
| Mice | 9 | 2023 | 81209 | 0.050 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 616 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2005 | 628 | 0.050 |
Why?
|
| Chemotaxis | 1 | 2005 | 598 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2005 | 720 | 0.050 |
Why?
|
| Injections, Intralesional | 2 | 2013 | 278 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 2864 | 0.050 |
Why?
|
| Estrogens | 1 | 2007 | 1520 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2023 | 832 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 6853 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 1483 | 0.040 |
Why?
|
| Animals | 9 | 2023 | 167960 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 2203 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 410 | 0.040 |
Why?
|
| Leucovorin | 1 | 2018 | 641 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2005 | 3215 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 429 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 715 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2023 | 2119 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2018 | 1631 | 0.030 |
Why?
|
| Receptors, OX40 | 1 | 2013 | 44 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 6216 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 22075 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 1723 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 8985 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 64981 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2005 | 11481 | 0.020 |
Why?
|
| Humans | 7 | 2022 | 760613 | 0.020 |
Why?
|
| Drug Costs | 1 | 2018 | 1185 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 5496 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 693 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2014 | 0.020 |
Why?
|
| src Homology Domains | 1 | 2010 | 361 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2013 | 547 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 2627 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 23374 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 1039 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1895 | 0.020 |
Why?
|
| Middle Aged | 3 | 2018 | 220359 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2009 | 616 | 0.020 |
Why?
|
| Rats | 1 | 2023 | 23709 | 0.020 |
Why?
|
| Female | 6 | 2018 | 391246 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 3607 | 0.020 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2005 | 77 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5508 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2005 | 186 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 2392 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2005 | 424 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2010 | 3602 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 2007 | 558 | 0.010 |
Why?
|
| RANK Ligand | 1 | 2005 | 318 | 0.010 |
Why?
|
| Granulocytes | 1 | 2005 | 551 | 0.010 |
Why?
|
| Uterus | 1 | 2007 | 651 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 653 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 16932 | 0.010 |
Why?
|
| Cell Division | 1 | 2010 | 4463 | 0.010 |
Why?
|
| Organ Size | 1 | 2007 | 2254 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 877 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8552 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 3583 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 22020 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8311 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 3047 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 1868 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11713 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2013 | 4642 | 0.010 |
Why?
|
| RNA Interference | 1 | 2005 | 2846 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2007 | 2560 | 0.010 |
Why?
|
| Monocytes | 1 | 2005 | 2575 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 6965 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15620 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2005 | 2860 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12531 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 4550 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13312 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 58980 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 4496 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 16548 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 4938 | 0.010 |
Why?
|
| Aged | 2 | 2018 | 169143 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2007 | 14374 | 0.010 |
Why?
|
| Male | 3 | 2018 | 359718 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 8950 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 18955 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 29661 | 0.010 |
Why?
|
| Adult | 1 | 2010 | 220007 | 0.000 |
Why?
|